Strategic Partnerships
AMPEL’s Genomic Platform (AGP) consists of RNA bioinformatic tools, AMPEL analytics, and machine learning (AI/ML) which analyze gene expression.
The AGP® evaluates disease status, identifies molecular pathways and predicts drug options.
Partnering Options
Ways to engage:
Drug Development:
Pharma Partnering
Product Development:
Clinical Care
Drug Development: Pharma Partnering
Decision Support for Disease Status, Molecular Pathways & Drug Options
Pre Clinical
(Target Optimization)
Phase 1
Clinical Trials
Phase 2-3
Clinical Trials
Marketed products
- Translation support on target activation and molecular pathway
- Mouse-Human gene expression
- Analyze RNA to predict what pathway(s) are being affected by the screened compounds
- Pharmacodynamics and early proof of concept
- Normals for PD & look for signals
- Observe corrections of subtle abnormalities with drug
Proprietary automated RNA analytics
- Screen candidates for clinical trial enrollment
- Disease agnostic and 7-10 day turnaround
- Improve odds of clinical trial success
- Complementary Biomarker
- Patient selection for drug options
Who We Work With
AMPEL seeks relationships with Pharmaceutical and Precision medicine companies:
• Co-Develop RNA analytic tests in desired disease areas
• License with field of use for specific conditions
• Use of AGP®, Bioinformatic tools and ML/AI Algorithms
Product Development: Clinical Care
Decision Support for Disease Status, Molecular Pathways & Drug Options
Clinical Care Site
Laboratory
(CLIA Certified)
Administration
- Simple blood draw or tissue biopsy in PAXGene® Tube or equivalent
- RNA Sequencing
- Data uploaded to AMPEL Genomic Platform® on HIPAA compliant Google Cloud
Proprietary automated RNA analytics
- Bioinformatic tools & machine learning algorithms
- Proprietary gene expression database (20K+)
- Interface with EMR
- Report to Clinical Care Site
- Billing and Collection
